Literature DB >> 26363191

L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.

Keun Hong Park1, Keon Sung Shin1, Ting Ting Zhao1, Hyun Jin Park1, Kyung Eun Lee1, Myung Koo Lee2.   

Abstract

L-DOPA causes neurotoxicity by modulating the Epac-ERK system in PC12 cells. This study investigated the effects of a single treatment with L-DOPA and multiple treatments with L-DOPA (MT-LD) on ERK1/2 and JNK1/2-c-Jun systems. In PC12 cells, a toxic L-DOPA concentration (200 μM) induced sustained ERK1/2 and JNK1/2 phosphorylation that was inhibited by the Epac inhibitor brefeldin A, but not by the PKA inhibitor H89. This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation. A non-toxic L-DOPA concentration (20 μM) induced c-Jun phosphorylation (Ser73) via transient ERK1/2 phosphorylation, whereas the toxic L-DOPA concentration induced c-Jun phosphorylation (Ser63) and c-Jun expression via Epac-sustained ERK1/2-JNK1/2 phosphorylation, which then enhanced cleaved caspase-3 expression. MT-LD (20 μM) initially enhanced c-Jun phosphorylation (Ser73) (for 1-4 days), but later (5-6 days) induced c-Jun phosphorylation (Ser63) and c-Jun expression. In the 6-hydroxydopamine-lesioned rat model of Parkinson's disease, L-DOPA administration (10 mg/kg) protected against neurotoxicity through c-Jun phosphorylation (Ser73) for 1-2 weeks. However, L-DOPA administration (10 or 30 mg/kg) showed neurotoxicity through c-Jun phosphorylation (Ser63) and c-Jun expression via ERK1/2 phosphorylation for 3-4 weeks. Thus, in PC12 cells, non-toxic L-DOPA treatment maintained cell survival through c-Jun phosphorylation (Ser73). By contrast, toxic L-DOPA treatment or MT-LD (20 μM) induced c-Jun phosphorylation (Ser63) and c-Jun expression via Epac-dependent sustained ERK1/2 and JNK1/2 phosphorylation, which subsequently led to cell death. These results were validated by those obtained after long-term L-DOPA administration in a rat model of Parkinson's disease. Our data indicate that L-DOPA causes neurotoxicity via the ERK1/2-c-Jun system in dopaminergic neuronal cells.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ERK1/2; Epac; L-DOPA; PC12 cells; Rat model of Parkinson's disease; c-Jun

Mesh:

Substances:

Year:  2015        PMID: 26363191     DOI: 10.1016/j.neuropharm.2015.09.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.

Authors:  Ting Ting Zhao; Kyung Sook Kim; Keon Sung Shin; Hyun Jin Park; Hyun Jeong Kim; Kyung Eun Lee; Myung Koo Lee
Journal:  BMC Complement Altern Med       Date:  2017-09-06       Impact factor: 3.659

2.  Regulation of cell proliferation and metastasis by microRNA-593-5p in human gastric cancer.

Authors:  Han Yu; Weiyuan Wei; Wenlong Cao; Zexu Zhan; Linhai Yan; Kun Wu; Dongyi Xie; Bin Cai; Yubo Xie; Qiang Xiao
Journal:  Onco Targets Ther       Date:  2018-10-24       Impact factor: 4.147

3.  Ethanol extract from Gynostemma pentaphyllum ameliorates dopaminergic neuronal cell death in transgenic mice expressing mutant A53T human alpha-synuclein.

Authors:  Hyun Jin Park; Ting Ting Zhao; Seung Hwan Kim; Chong Kil Lee; Bang Yeon Hwang; Kyung Eun Lee; Myung Koo Lee
Journal:  Neural Regen Res       Date:  2020-02       Impact factor: 5.135

4.  S-adenosylmethionine administration inhibits levodopa-induced vascular endothelial growth factor-A expression.

Authors:  Yuanliang Yan; Qijia Yan; Long Qian; Yueping Jiang; Xi Chen; Shuangshuang Zeng; Zhijie Xu; Zhicheng Gong
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

5.  Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells.

Authors:  Jingwangwei Liu; Yujia Lu; Min Tang; Fanghao Shao; Dongzi Yang; Shuchang Chen; Ziyi Xu; Leilei Zhai; Juanjuan Chen; Qian Li; Wei Wu; Haimin Chen
Journal:  Mar Drugs       Date:  2022-03-31       Impact factor: 6.085

Review 6.  Epac: A Promising Therapeutic Target for Vascular Diseases: A Review.

Authors:  Yunfeng Pan; Jia Liu; Jiahui Ren; Yun Luo; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2022-07-14       Impact factor: 5.988

7.  Re-Cloning the N27 Dopamine Cell Line to Improve a Cell Culture Model of Parkinson's Disease.

Authors:  Lu Gao; Wenbo Zhou; Breanna Symmes; Curt R Freed
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

8.  Hint1 expression inhibits proliferation and promotes radiosensitivity of human SGC7901 gastric cancer cells.

Authors:  Xiaowei Wei; Jin Zhou; Lingzhi Hong; Zhi Xu; Huanyu Zhao; Xiaomin Wu; Jinfei Chen
Journal:  Oncol Lett       Date:  2018-06-05       Impact factor: 2.967

Review 9.  Role of Mitogen Activated Protein Kinase Signaling in Parkinson's Disease.

Authors:  Anastasiia Bohush; Grazyna Niewiadomska; Anna Filipek
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.